These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
64. Incidence of endophthalmitis after intravitreal application of anti VEGF therapy at the University Clinical Center in Tuzla, Bosnia and Herzegovina. Terzić S; Pilavdžić A; Nadarević Vodenčarević A Med Glas (Zenica); 2015 Aug; 12(2):202-5. PubMed ID: 26276660 [TBL] [Abstract][Full Text] [Related]
65. Intraocular pressure in patients with neovascular age-related macular degeneration switched to aflibercept injection after previous anti-vascular endothelial growth factor treatments. Rusu IM; Deobhakta A; Yoon D; Lee M; Slakter JS; Klancnik JM; Thompson D; Freund KB Retina; 2014 Nov; 34(11):2161-6. PubMed ID: 25072648 [TBL] [Abstract][Full Text] [Related]
66. NONINFECTIOUS VITRITIS AFTER INTRAVITREAL INJECTION OF ANTI-VEGF AGENTS: Variations in Rates and Presentation by Medication. Williams PD; Chong D; Fuller T; Callanan D Retina; 2016 May; 36(5):909-13. PubMed ID: 27115856 [TBL] [Abstract][Full Text] [Related]
67. Sustained intraocular pressure elevation in eyes treated with intravitreal injections of anti-vascular endothelial growth factor for diabetic macular edema in a real-life setting. Vo Kim S; Fajnkuchen F; Sarda V; Qu-Knafo L; Bodaghi B; Giocanti-Aurégan A Graefes Arch Clin Exp Ophthalmol; 2017 Nov; 255(11):2165-2171. PubMed ID: 28831613 [TBL] [Abstract][Full Text] [Related]
68. The early effects of intravitreal anti vascular endothelial growth factor agents on intraocular pressure and central corneal thickness. Omay E; Elgin U; Sen E; Yilmazbas P Int Ophthalmol; 2016 Oct; 36(5):665-70. PubMed ID: 26780098 [TBL] [Abstract][Full Text] [Related]
69. Is there tachyphylaxis to intravitreal anti-vascular endothelial growth factor pharmacotherapy in age-related macular degeneration? Schaal S; Kaplan HJ; Tezel TH Ophthalmology; 2008 Dec; 115(12):2199-205. PubMed ID: 18930553 [TBL] [Abstract][Full Text] [Related]
70. Endophthalmitis associated with intravitreal anti-vascular endothelial growth factor therapy injections in an office setting. Pilli S; Kotsolis A; Spaide RF; Slakter J; Freund KB; Sorenson J; Klancnik J; Cooney M Am J Ophthalmol; 2008 May; 145(5):879-82. PubMed ID: 18329624 [TBL] [Abstract][Full Text] [Related]
71. Plasma levels of vascular endothelial growth factor before and after intravitreal injection of bevacizumab, ranibizumab and pegaptanib in patients with age-related macular degeneration, and in patients with diabetic macular oedema. Zehetner C; Kirchmair R; Huber S; Kralinger MT; Kieselbach GF Br J Ophthalmol; 2013 Apr; 97(4):454-9. PubMed ID: 23385630 [TBL] [Abstract][Full Text] [Related]
72. Open Payments Database: Anti-Vascular Endothelial Growth Factor Agent Payments to Ophthalmologists. Singh N; Chang JS; Rachitskaya AV Am J Ophthalmol; 2017 Jan; 173():91-97. PubMed ID: 27697472 [TBL] [Abstract][Full Text] [Related]
73. Retinal function and morphology in rabbit after intravitreal injection of VEGF inhibitors. Myers AC; Lövestam Adrian M; Bruun A; Ghosh F; Andréasson S; Ponjavic V Curr Eye Res; 2012 May; 37(5):399-407. PubMed ID: 22510009 [TBL] [Abstract][Full Text] [Related]
74. Anti-VEGF Agents and the Risk of Arteriothrombotic Events. Zarbin MA Asia Pac J Ophthalmol (Phila); 2018; 7(1):63-67. PubMed ID: 29405046 [TBL] [Abstract][Full Text] [Related]
75. Physician Utilization Patterns for VEGF-Inhibitor Drugs in the 2012 United States Medicare Population: Bevacizumab, Ranibizumab, and Aflibercept. Baisiwala S; Bundorf MK; Pershing S Ophthalmic Surg Lasers Imaging Retina; 2016 Jun; 47(6):555-62. PubMed ID: 27327285 [TBL] [Abstract][Full Text] [Related]
76. Recovery of plasma vascular endothelial growth factor concentrations during aflibercept loading phase and after the transition to bimonthly treatment for neovascular age-related macular degeneration. Roald AB; Aass HC; Moe MC Br J Ophthalmol; 2015 Dec; 99(12):1610-3. PubMed ID: 25966740 [TBL] [Abstract][Full Text] [Related]
77. Serum and plasma vascular endothelial growth factor concentrations before and after intravitreal injection of aflibercept or ranibizumab for age-related macular degeneration. Wang X; Sawada T; Sawada O; Saishin Y; Liu P; Ohji M Am J Ophthalmol; 2014 Oct; 158(4):738-744.e1. PubMed ID: 24973606 [TBL] [Abstract][Full Text] [Related]
78. Vascular endothelial growth factor plasma levels before and after treatment of retinopathy of prematurity with ranibizumab. Zhou Y; Jiang Y; Bai Y; Wen J; Chen L Graefes Arch Clin Exp Ophthalmol; 2016 Jan; 254(1):31-6. PubMed ID: 25851862 [TBL] [Abstract][Full Text] [Related]
79. Intravitreal Aflibercept Injection in Diabetic Macular Edema Patients with and without Prior Anti-Vascular Endothelial Growth Factor Treatment: Outcomes from the Phase 3 Program. Do DV; Nguyen QD; Vitti R; Berliner AJ; Gibson A; Saroj N; Soo Y; Boyer DS Ophthalmology; 2016 Apr; 123(4):850-7. PubMed ID: 26832658 [TBL] [Abstract][Full Text] [Related]
80. Prefilled syringes for intravitreal drug delivery. Sassalos TM; Paulus YM Clin Ophthalmol; 2019; 13():701-706. PubMed ID: 31114147 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]